We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Hemostasis Analyzers Market Driven by Increasing Awareness of Blood Disorder Conditions

By LabMedica International staff writers
Posted on 09 Feb 2023
Print article
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)
Image: The global hemostasis analyzers market is expected to reach close to USD 6 billion in 2026 (Photo courtesy of Pexels)

Hemostasis analyzers are devices used for measuring clotting mechanisms of hemostasis in order to detect clotting deficiencies. The body’s natural ability to quickly stop bleeding in order to stop serious blood loss is known as hemostasis. Hemostasis analyzers are used to perform tests such as APTT tests, D dimer tests, platelet function tests, fibrinogen tests, prothrombin time tests, and other tests using optical technology, mechanical technology, electrochemical technology, and other technologies. Within hemostasis analyzers, the main products are clinical laboratory analyzers, point-of-care testing analyzers, and consumables. Clinical laboratory analyzers are used to calculate the concentration of certain substances in various samples. The various end users of hemostasis analyzers are hospitals and clinics, diagnostic centers, research and development organizations and ambulatory surgical centers, among others.

The global hemostasis analyzers market is expected to reach USD 5.97 billion in 2026, driven by the increasing awareness of blood disorder conditions such as Hemophilia and Von Willebrand disease (vWD) which are genetic disorders and not well known to people. This results in late diagnosis of blood disorders and affects patient outcomes. The increasing awareness is expected to improve the diagnosis rate of blood disorders, thereby driving the demand for hemostasis analyzers. However, recalls of defective devices could act as a restraint to the growth of the hemostasis analyzers market. These are the latest findings of ReportLinker (Lyon, France), a market research solution provider.

The hemostasis analyzers market consists of sales of complete blood count (CBC), factor v assay, fibrinogen level, prothrombin time (PT or PT-INR), platelet count, and thrombin time. Manufacturers of hemostasis analyzers are developing portable, handheld hemostasis analyzers which are convenient for carrying anywhere and are small enough to fit in a person's palm. These portable hemostasis analyzers offer a quicker and easier testing process, and facilitate independent analysis of results. Geographically, North America dominated the global hemostasis analyzers market in 2022 with the largest share, followed by Western Europe with the second-largest share.

Related Links:
ReportLinker 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.